Delving into the Latest Updates on Curcumin C3 complex with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Curcumin C3 ®, Curcumin/Demethoxycurcumin/Bisdemethoxycurcumin

Target

NF-κB x bFGF x mTOR

Action

inhibitors

Mechanism

NF-κB inhibitors(Nuclear factor NF-kappa-B complex inhibitors), bFGF inhibitors(Fibroblast growth factor 2 inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Cervical Intraepithelial NeoplasiaHuman Papillomavirus-Related Cervical CarcinomaCutaneous Squamous Cell Carcinoma

Inactive Indication

Psoriasis vulgarisRadiodermatitis

Originator Organization

Lsu Health Shreveport

Active Organization

Emory University

Lsu Health Shreveport

Inactive Organization

University of Rochester

University of Pennsylvania

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology.

Start Date01 Sep 2025

Sponsor / Collaborator

Emory University

NCT03598309

/ Active, not recruitingPhase 2IIT

Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers

The purpose of this study is to find out if an investigational combination drug called Lovaza (made with fish oils)+Curcumin C3 Complex (made from a root called curcumin) can help reduce the size of lung nodules. Researchers also want to find out if the combination of Lovaza+Curcumin C3 Complex is safe and tolerable.

Start Date05 Jun 2019

Sponsor / Collaborator

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT01490996

/ CompletedPhase 1/2IIT

A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.

Oral curcumin (complex C3, Sabinsa Corp, Utah) will be given to patients with inoperable colorectal metastases who will be commencing standard care oxaliplatin-based (FOLFOX) chemotherapy for up to 12 cycles(approximately 6 months) of treatment.
Primary measurements focus on safety and tolerability. These will be recorded in real-time and report the number and severity of adverse events.
Secondary measurements will include efficacy, (measured by response rate with RECIST and overall survival in months) supported by biomarker analysis.

Start Date01 Feb 2012

Sponsor / Collaborator

University of Leicester

100 Clinical Results associated with Curcumin C3 complex

Login to view more data

100 Translational Medicine associated with Curcumin C3 complex

Login to view more data

100 Patents (Medical) associated with Curcumin C3 complex

Login to view more data

18

Literatures (Medical) associated with Curcumin C3 complex

31 Oct 2023·Journal of toxicology

Assessment of Safety Profile of Activated Curcumin C3 Complex (AC3®), Enriched Extract of Bisdemethoxycurcumin from the Rhizomes of Curcuma longa

Article

Author: Pandey, Anjali ; Majeed, Muhammed ; Ibrahim A, Muhamad ; Thazhathidath, Smitha ; Bani, Sarang

The present work was carried out to investigate the toxic effects of Activated Curcumin C3 Complex (AC3®) through the methods of acute, subacute, subchronic, reproductive/developmental toxicity, and genotoxicity when administered orally in experimental rodents. The studies were carried out in line with OECD principles of good laboratory practice. A single-dose acute oral toxicity study was conducted on female Wistar rats that produced no toxic effects after 14 days (the observation period) of treatment. Subacute, subchronic, and reproductive/developmental studies were conducted in Wistar rats, divided equally into vehicle control, 125, 250, and 500 mg/kg dose groups along with recovery groups for vehicle control and high dose. In all the studies, there were no abnormal clinical signs/behavioral changes, reproductive and developmental parameters, or gross and histopathological changes. Likewise, no alteration was found in the body weight, hematology, and other biochemical parameters. Also, it did not show mutagenicity in the in vitro AMES test or clastogenicity and aneugenicity in the in vivo micronucleus test, indicating that AC3® did not induce any genotoxic effects. This revealed that oral administration of AC3® is safe in rodents, nonmutagenic, and had no observed adverse effects under experimental conditions.

01 Apr 2023·The Journal of frailty & aging

Effects of Curcumin C3 Complex® on Physical Function in Moderately Functioning Older Adults with Low-Grade Inflammation — A Pilot Trial

Article

Author: Sandesara, B ; Lin, Y ; Anton, S D ; Leeuwenburgh, C ; Qiu, P ; Mankowski, R T ; Sibille, K T ; Hsu, F-C

BACKGROUND:

Natural dietary compounds that can modulate the inflammation process have the potential to improve physical function through a number of biological pathways, and thus may represent an alternative approach to avert functional decline compared to more time-burdening lifestyle interventions. In this pilot trial, we tested the feasibility and explored the effect of a nutritional compound, Curcumin C3 Complex® for improving physical function and muscle strength in moderately functioning older adults with low-grade inflammation.

METHODS:

Moderately functioning (short physical performance battery, SPPB <10) and sedentary older adults (>65 years) with low-grade systemic inflammation (c-reactive protein >1mg/dL) were randomized to receive Curcumin C3 Complex® (n=9) (1000mg/day) or placebo (n=8) groups for 12 weeks. All participants (age range: 66-94 years, 8 females and 9 males) underwent functional testing (SPPB and walking speed by the 400-meter walk test) and lower-limb strength (knee flexion and extension peak torque by the Biodex test) at baseline and 12 weeks. Venous blood was collected at baseline, 4, 8 and 12 weeks for safety blood chemistry analyses and biomarkers of inflammation.

RESULTS:

A total of 17 participants were randomized and completed the study. Adherence was high (> 90%) and there were no adverse events reported or abnormal blood chemistries reported. Based on effect sizes, participants in the Curcumin C3 Complex® group demonstrated large effect sizes in the SPPB (Cohen's effect size d=0.75) and measures of knee extension (d=0.69) and flexion peak torque (d=0.82). Effect sizes for galectin-3 (d=-0.31) (larger decrease) and interleukin-6 (d=0.38) (smaller increase) were small in the Curcumin C3 Complex® group compared to placebo.

CONCLUSION:

This pilot trial suggests that there were no difficulties with recruitment, adherence and safety specific to the study protocol. Preliminary findings warrant a Phase IIb clinical trial to test the effect of Curcumin C3 Complex® on physical function and muscle strength in older adults at risk for mobility disability.

20 Sep 2022·Archives of endocrinology and metabolism

Curcumin supplementation reduces blood glucose and serum lipids of Brazilian women with high waist circumference: a randomized clinical trial

Article

Author: Trindade, Neidiane Rosa ; Silva, Maria Sebastiana ; de Sousa, Menandes Alves ; Guillo, Lídia Andreu ; de Sousa Guardiano Reis, Pamela Cristina ; Alves, Ana Gabriella Pereira

Objective:

To evaluate the effect of curcumin supplementation on the body compositions and biochemical parameters of Brazilian women with high waist circumferences.

Methods:

This is a blind, randomized, placebo-controlled clinical trial conducted in 2016 with 35 Brazilian women with high waist circumference (WC). In total, 80 participants were randomized [38 in the placebo group (PG) and 42 in the supplemented group (SG)], but at the end of the protocol, 20 individuals in the PG and 15 in the SG were evaluated. The sample consumed one capsule of curcumin (500 mg/day) (Curcumin C3 Complex®) or a placebo for 90 days. Body weight, height, body mass index, WC, body fat, fat free mass, fasting glucose (FG), lipid profile [triglycerides (TGs), total cholesterol (TC), HDL-c and LDL-c], physical activity level and food intake (energy, carbohydrate, total fat and protein) data were evaluated before and after the intervention.

Results:

Curcumin supplementation reduced body mass (p < 0.040) but did not alter other anthropometric parameters or body composition (p ≥ 0.050). In relation to the biochemical profile, the SG saw reductions in FG (p < 0.001), TGs (p < 0.001) and TC (p = 0.001) compared with the PG. At the baseline and during the intervention, the practice of physical activity and food intake did not differ between the SG and PG (p ≥ 0.050).

Conclusion:

Curcumin supplementation improved the blood glucose and lipid profile of Brazilian women with high WC, without altering body composition. New studies with larger sample sizes and longer durations are important for identifying more robust data regarding the proposal of this work.

100 Deals associated with Curcumin C3 complex

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cervical Intraepithelial Neoplasia	Phase 2	United States	Emory University	01 Sep 2025
Human Papillomavirus-Related Cervical Carcinoma	Phase 2	United States	Emory University	01 Sep 2025
Radiodermatitis	Phase 2	United States	University of Rochester	01 Jan 2008
Psoriasis vulgaris	Phase 2	United States	University of Pennsylvania	01 Oct 2005
Cutaneous Squamous Cell Carcinoma	Preclinical	United States	Lsu Health Shreveport	01 Aug 2015